Conference Reports for NATAP

Back

ICAAC 2015 55th Interscience Conference on Antimicrobial Agents and Chemotherapy September 17-21, 2015 San Diego, CA     A Dose Escalation Study of Cyclophosphamide (CTX) to Enhance SB-728-T Engraftment - (09/30/15)   New HCV NS5A Inhibitor - (09/30/15)   Pharmacokinetics, Safety and Tolerability of EDP-239, a Novel Hepatitis C (HCV) NS5A inhibitor, in Patients with HCV Infection - (09/30/15)   Pharmacokinetics, Safety, and Tolerability of EDP-239, a novel Hepatitis C NS5A inhibitor, in Healthy Volunteers - (09/30/15)   Population Pharmacokinetic Assessment of Factors Associated with Tenofovir Clearance in Pregnant and Postpartum Women with HIV infection in IMPAACT P1026s - (09/28/15)   Safety of Ledipasvir/Sofosbuvir with and without Ribavirin for the Treatment of Patients with Chronic HCV Genotype 1 Infection: An Analysis of the Phase 3 ION trials - (09/25/15)   No Difference in Safety Profiles Comparing 12- and 24-Week HCV Treatment Durations in HCV Genotype 1 and HIV-1 Co-Infected Patients: Results From TURQUOISE-I - (09/25/15)   Relationship between Type of Antiretroviral Therapy, Drug-Drug Interactions, and Hospitalizations - - (09/25/15)   Are Week-12 Results Adequate for Phase 2 Integrase Inhibitor Trials? - written by Mark Mascolini - (09/25/15)   HIV Hospital Mortality Flat From 1993 to 2013, But Non-AIDS Death Rate Surges...... Over that period the proportion of in-hospital deaths attributable to non-AIDS causes rose from 43% to 70.5% (P < 0.0001) - written by Mark Mascolini - (09/25/15)   Lower Tenofovir Levels in Pregnant Women Taking a Boosted PI - written by Mark Mascolini - (09/25/15)   Contraindicated Drugs Combos Tied to Higher Hospital Rate in HIV+ Veterans - written by Mark Mascolini - (09/25/15)   Success of NRTI-sparing Regimens Containing Raltegravir in Therapy-experienced Patients in a German Cohort - (09/24/15)   Kinetics of release of antiretroviral drugs through a silicone vaginal ring..... Preliminary Results of a non-toxic Silicone vaginal ring to deliver antiviral drugs, protect women against HIV & herpes - (09/24/15)   Week 12 as an Early Predictor of Week 24 Outcomes in Trials of an Integrase Strand Transfer Inhibitor for HIV - (09/24/15)   Doravirine Does Not Have a Clinically Meaningful Effect on the Pharmacokinetics of Atorvastatin - (09/24/15)   Alarmingly High Comorbidity Rates Among HIV+ - (09/24/15)   Comorbidities of Patients with Human Immunodeficiency Virus (HIV) in the USA - a Longitudinal Analysis of Prevalent HIV Patients Over 11 Years - (09/24/15)   Food Does Not Affect the Bioavailability of Doravirine: Results from Two Pharmacokinetic Studies in Healthy Subjects - (09/21/15)   Protection Against Flu But Not HBV in Vaccinated Perinatally HIV-Infected Children - (09/21/15)   Cabotegravir Has No Effect on Cardiac Repolarization in Healthy Subjects - (09/21/15)   Switching to Abacavir/Dolutegravir/Lamivudine Fixed Dose Combination (ABC/DTG/3TC FDC) from a PI, INI or NNRTI Based Regimen Maintains HIV Suppression - (09/21/15)   Simplification To TDF/FTC/RPV From TDF/FTC Or ABC/3TC Plus RTG In A Cohort Study - (09/21/15)   Safety of Once-Daily Elvitegravir, Cobicistat, Emtricitabine, and Tenofovir Alafenamide in Participants With Glomerular Filtration Rate <50 mL/min: 48-Week Results - (09/21/15)   Switching From Atripla to a Tenofovir Alafenamide-Based Single-Tablet Regimen: Week-48 Data in Virologically Suppressed Adults - (09/21/15)   Elvitegravir (EVG)/Cobicistat (COBI)/Emtricitabine (FTC)/Tenofovir Disoproxil Fumarate (TDF) Is Superior to Ritonavir (RTV)-Boosted Atazanavir (ATV) Plus FTC/TDF in Treatment-Naïve Women With HIV-1 Infection (WAVES Study) - (09/21/15)   HIV Hospital Mortality Flat From 1993 to 2013, But Non-AIDS Death Rate Surges - Written by Mark Mascolini - (09/21/15)   New Assay Probing HIV DNA Detects Mutations Found Earlier in Plasma RNA - (09/21/15)   FIB-4 Linked to All-Cause Mortality in Large Italian HIV/HCV Cohort - Written by Mark Mascolini - - (09/21/15)   No Transmission of Integrase-Resistant HIV Seen in California Cohort - Written by Mark Mascolini - - (09/21/15)   Better HIV Control, Better Bone Changes After Switch From Atripla to E/C/F/TAF - Written by Mark Mascolini - - (09/21/15)   Switch From Raltegravir to Rilpivirine Regimen Safe, Effective in Cohort Study - Written by Mark Mascolini - - (09/21/15)   Over 85% in German Group Under 50 Copies on NRTI-Sparing Raltegravir Combo - Written by Mark Mascolini - - (09/21/15)   Restored TB-Specific CD4 Response Linked to TB-IRIS Soon After ART Starts - Written by Mark Mascolini - - (09/21/15)   Doubled Hypogonadism Rate in Middle-Aged Men With HIV--Fat Is a Factor - Written by Mark Mascolini - - (09/21/15)   Switch From Raltegravir to Rilpivirine Regimen Safe, Effective in Cohort Study - Written by Mark Mascolini - - (09/21/15)   E/C/F/TAF Kind to Kidneys of People With Stable Renal Impairment - Written by Mark Mascolini - - (09/21/15)